The lifetime incidence of venous throm-boembolism for both men and women is estimated at
1 per 1000. 1 Increasing our understanding of the precipitating risk factors, as well as …

Background Two studies recently published in the British Medical Journal, a retrospective
cohort study using information from the Danish registries1 and the MEGA case-control study …

Although the risk of venous thromboembolism is increased among oral contraceptive users
compared with nonusers who are not pregnant and not taking hormones, and some data …

Introduction Substantial evidence suggests that drospirenone-containing oral contraceptives
may cause a higher risk of venous thrombotic events than earlier-generation oral …

Background Two recent studies, a cohort study from Denmark, and a case-control study from
The Netherlands, have reported increased risks of venous thromboembolism (VTE) among …

Background Four studies published since December, 1995, reported that the incidence of
venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) …

Background The effects of fourth‐generation drospirenone‐containing combined oral
contraceptives (COC s) on the risk of venous thromboembolism (VTE) are controversial …

In the last decade, the contribution of the progestin component of oral contraceptives (OCs)
to the risk of venous thromboembolism (VTE) has come under scrutiny. The publication of 4 …

New epidemiological studies have demonstrated a higher risk of venous thromboembolism
among users of oral contraceptives (O Cs) with third-generation progestogens desogestrel …

PIP: In response to unpublished data revealing a doubling of venous thromboembolism risk
with oral contraceptives (OCs) containing desogestrel or gestodene compared with …